Navigation Links
Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery
Date:10/4/2010

MOUNTAIN VIEW, Calif., Oct. 4 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd. (DSP) and SanBio, Inc. (SanBio) today announced that they have entered into an option agreement to co-develop a new cell therapy for stroke recovery.

Under the agreement, DSP has received an option for exclusive U.S. and Canadian marketing rights to SB623.  SB623 is a promising cell therapy drug candidate being developed by SanBio for disabilities caused by stroke for which there are currently no effective therapies.  SB623 is an allogeneic cell product, derived from bone marrow stromal cells isolated from healthy donors.  Unlike autologous cell therapy, which requires individualized cell preparation, SB623 production can be scaled, enabling a more cost effective therapy for stroke patients. In preclinical studies to date, SB623 has dramatically improved function in animal models of stroke disability with no significant adverse effects.  The US FDA has recently permitted the initiation of human clinical trial of this innovative cell therapy.

"We expect to exercise this option based on results of a Phase I/IIa trial, already in preparation, and, if these results are favorable, intend to secure exclusive marketing rights to SB623 in the U.S. and Canada," said Masayo Tada, President and Chief Executive Officer of DSP.  "This therapy is an exciting, innovative approach to a profound unmet need for millions of patients. We believe SB623 can contribute to improved health and well being for people throughout the U.S. and Canada."

"Also, for DSP, this therapy is an excellent strategic fit. Our group has been developing business in North America through our subsidiary Sepracor Inc., soon to be called Sunovion Pharmaceuticals Inc.  The addition of this product should enhance our leadership position in the central nervous system (CNS) field, one of our highest priority therapeutic areas."

Keita Mori, co-CEO of SanBio, said, "DSP is an
'/>"/>

SOURCE SanBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
2. PDL BioPharma Completes October 1 Special Dividend Payment
3. Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry
4. Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
5. Syndax Pharmaceuticals to Present at BIO Investor Forum
6. ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
7. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
8. Reportlinker Adds Shire plc: PharmaVitae Profile
9. Kevin Kruse Named Executive Director of the Society of Pharmaceutical and Biotech Trainers
10. Genesis Biopharma Announces $700K Private Financing
11. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Earlier this month, a report was created ... U.S. Air Force on the performance of vehicles using ... type of fuel made from mustard seeds, offered great ... America’s Eco friendly future. In fact, every branch of ... independent of foreign oil over the next few years. ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Whitehouse Laboratories ... long term partnership with PTI Inspection Systems ... with state of the art leak testing method development ... art instruments currently available. As part of this agreement, ... High Voltage Leak Detection Instrument developed and manufactured ...
(Date:8/27/2014)... Aug. 27, 2014 Rhythm, a biopharmaceutical company ... deficiencies that result in metabolic disorders, announced today that ... with the U.S. Securities and Exchange Commission (SEC) relating ... its common stock. The number of shares to be ... not yet been determined. Citigroup and Cowen ...
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2
... Today, Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced ... issued an approvable letter for Once-A-Day,LUVOX(R) CR (fluvoxamine ... Pharmaceuticals, Inc. are seeking marketing,approval for the treatment ... obsessive compulsive disorder (OCD)., The FDA requested ...
... Protein Exports, and Biofuels Key Issues in 2008, ... country,of origin labeling and developments in biofuels are some ... & Agribusiness Outlook., The Outlook is produced annually ... provides information and analysis covering all of,the major sectors ...
... SOUTH SAN FRANCISCO, Calif., Dec. 21 Anesiva,Inc. ... of its public offering,of 11,111,111 shares of its ... their option to purchase an additional 1,234,568 shares.,The ... from the sale of the aggregate 12,345,679 shares ...
Cached Biology Technology:FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 2Rabobank Releases Annual North American Food & Agribusiness Outlook 2Rabobank Releases Annual North American Food & Agribusiness Outlook 3Rabobank Releases Annual North American Food & Agribusiness Outlook 4
(Date:8/28/2014)... the most commonly diagnosed learning disability in the ... occurs when the regions of the brain that ... use of non-invasive functional neuroimaging tools has helped ... However, most prior work has focused on only ... gap in our understanding of how multiple brain ...
(Date:8/28/2014)... mould in homes could pose a significant health risk to ... the Journal of Allergy and Clinical Immunology . , ... different countries, the research has found that the presence of ... asthma sufferers, as well as increasing the likelihood of developing ... team at the University of Exeter Medical School and is ...
(Date:8/28/2014)... more action is needed to ensure safeguards are in ... in PLOS ONE , researchers from Monash University, ... - combining results from different studies - to look ... areas, to determine whether they actually protect biodiversity. ... protecting an area from human exploitation made common sense, ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2Indoor mold poses health risk to asthma sufferers 2Protected areas proven to protect biodiversity 2
... innovative systems biology approach to understanding the carbohydrate structures ... how inflammatory illnesses and cardiovascular disease develop in humans. ... University at Buffalo chemical engineers. , Supported by ... ultimate goal of the project is to define novel ...
... Eastman Dental Center,s Hyun (Michel) Koo, D.D.S, Ph.D., $1.6 ... the single most prevalent and costly oral infectious disease ... results from the interaction of specific bacteria (such as ... using sucrose to help them, and other pathogens, to ...
... N.J. Dr. Dilhan Kalyon, Professor of Chemical ... Institute at Stevens Institute of Technology, has won ... The award, sponsored by Shell Global Solutions, Inc., ... made a significant impact in the field of ...
Cached Biology News:Researchers apply systems biology and glycomics to study human inflammatory diseases 2Researchers apply systems biology and glycomics to study human inflammatory diseases 3Eastman Dental Center awarded $1.6 million to find ways to prevent cavities 2
pETDuet-1 is designed for the coexpression of two target genes....
... Recognizes K+ Cl- ... shows no significant sequence ... or CCC.,SPECIES REACTIVITIES: The ... conserved in human, mouse, ...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
oligophrenin-1 (H-100)...
Biology Products: